Related Experiment Video
Updated: Jul 18, 2026
Murine Model of Epicutaneously-Induced Immunomodulation
Published on: June 24, 2025
[Immune regulating activity of a novel organoselenium compound ethaselen-1 in C57/BL mice]
Yi-rui Wang1, Jun-jun Xiao, Xiao-min Dong
1Deparptment of Chemical Biology, School of Pharmaceutical Sciences, Peking University, Beijing 100083, China.
Objective:
To detect the Immune regulating activity of ethaselen-1 (Eb1), a novel organoselenium compound, in C57/BL mice transplanted with Lewis lung cancer(LLC).
Methods:
The LLC transplanted C57/BL mice models were established, and the mice was randomly divided into four groups, including high dose Eb1 group (25.0 mg/kg),low dose Eb1 group (12.5 mg/kg), positive control group (levamisole, LMS, 2.0 mg/kg) and negative control group(solvent). Intraperitoneal injections (ip.) of the four pharmaceuticals were performed once a day through the abdominal wall separately, from the second to the eighth day after cancer was transplanted. On the eleventh day, six mice of each group were killed and relative weight of spleen, transforming activity of spleen lymphocytes, NK cell activity, LAK cell activity and percentage of CD4(+)CD8(+)T lymphocyte were detect.
Results:
Compared with the control group, high dose Eb1 could obviously increase the relative weight of spleen (150.59% and 122.55%), transforming activity of spleen lymphocytes(162.25% and 561.98%), NK cell activity(78.60% and 219.42%) and percentage of CD4(-)/CD8(+) T lymphocyte(104.72% and 105.87%) in normal mice and LLC mice. Compared with the control group, high dose Eb1 could also increase LAK cell activity of LLC mice by 195.11%.
Conclusion:
The novel organoselenium compound Eb1 has immune regulating activity in vivo.
